Speeding innovation for industry
Success | Micro-nanoelectronics
Comprehensive and personalized system for autonomous T1D management
Diabeloop is a French independent company developing disruptive technological innovations to automate the treatment of Type one diabetes.
Its first product, the DBLG1 System, is an integrated system that allows glycemic control in an automatic and highly efficient way. The core of this innovation is an Artificial Intelligence hosted on a terminal that connects via bluetooth with a continuous glucose meter (CGM) and an insulin pump.
The algorithm makes and executes the many therapeutic decisions that the patients currently have to handle by themselves. Patients are only expected to log meals and physical activities.
Partnered with the CERITD led by Doctor Charpentier, Diabeloop medical director and founder, and with CEA-Leti leading university diabetes centers (French and international), Diabeloop has formed a unique combination of expertise in medical research, clinical development and deep maths. Together, they have achieved a radical innovation, an algorithm that fine-tunes the glucose management in a proactive way thanks to personalization to the individuals physiology, self-learning capabilities and integration to patients' care path and everyday life.
Resources and skills
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.